Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.48 |
| ▸ | TUBB4A | P04350 | 3/20 | 0.46 |
| ▸ | TUBB | P07437 | 3/20 | 0.46 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.46 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.46 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.46 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.46 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.46 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.46 |
| ▸ | TUBB8 | Q3ZCM7 | 3/20 | 0.46 |
| ▸ | TUBA3E | Q6PEY2 | 3/20 | 0.46 |
| ▸ | TUBA1A | Q71U36 | 3/20 | 0.46 |
| ▸ | TUBA1C | Q9BQE3 | 3/20 | 0.46 |
| ▸ | TUBB6 | Q9BUF5 | 3/20 | 0.46 |
| ▸ | TUBB2B | Q9BVA1 | 3/20 | 0.46 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30581674 | 1.00 | ENPP2 (0.48) | ENPP2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL31040235 | 0.87 | ENPP2 (0.47) | ENPP2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL5410987 | 0.85 | ENPP2 (0.48) | ENPP2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL3068498 | 0.85 | ENPP2 (0.48) | ENPP2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL29957363 | 0.85 | ENPP2 (0.48) | ENPP2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL28154939 | 0.84 | HDAC4 (0.39) | ENPP2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL22925812 | 0.84 | CA12 (0.44) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL12775740 | 0.83 | TRPA1 (0.37) | HDAC4HDAC8ALDH1A1SMN1; SMN2TRPA1 | |
| SCHEMBL4976111 | 0.82 | ALDH1A1 (0.49) | ENPP2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL12775739 | 0.80 | ALDH1A1 (0.46) | ALDH1A1KMT2APOLBSMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 248 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118515534-B | Multi-tooth ligand, multi-tooth ligand metal catalyst, and preparation method and application thereof | 华南理工大学 | 2024-11-05 | — | — | CN | claimed |
| CN-118515534-A | Multi-tooth ligand, multi-tooth ligand metal catalyst, and preparation method and application thereof | 华南理工大学 | 2024-08-20 | — | — | CN | claimed |
| EP-1506176-B1 | AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | PFIZER ITALIA SRL (IT) | 2013-04-24 | — | — | EP | claimed |
| US-12435060-B2 | Acylamino bridged heterocyclic compound, and composition and application thereof | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2025-10-07 | — | — | US | disclosed |
| US-20250206724-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2025-06-26 | — | — | US | disclosed |
| CN-118515534-B | Multi-tooth ligand, multi-tooth ligand metal catalyst, and preparation method and application thereof | 华南理工大学 | 2024-11-05 | — | — | CN | disclosed |
| CN-118515534-A | Multi-tooth ligand, multi-tooth ligand metal catalyst, and preparation method and application thereof | 华南理工大学 | 2024-08-20 | — | — | CN | disclosed |
| EP-3901147-B1 | ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2023-11-22 | — | — | EP | disclosed |
| WO-2023186773-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2023-10-05 | — | — | WO | disclosed |
| US-20230026425-A1 | ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2023-01-26 | — | — | US | disclosed |
| CN-113166116-B | Amido bridged heterocyclic compound, and composition and application thereof | 北京赛特明强医药科技有限公司 | 2022-12-27 | — | — | CN | disclosed |
| US-6555577-B1 | For treatment and/or prevention of conditions mediated by the Peroxisome Proliferator-Activated Receptors (PPAR), such as diabetes and/or obesity; 3-(4-(3-Biphenyl-4-yl-but-2-enyloxy)-phenyl)-2-butoxy-propionic acid for example | NOVO NORDISK A/S (DE) | 2003-04-29 | — | — | US | disclosed |
| US-20030073862-A1 | Compounds | BIOVITRUM AB (SE) | 2003-04-17 | — | — | US | disclosed |
| WO-2003015715-A2 | TETRAHYDROQUINOLINE DERIVATIVES AS ANTITHROMBOTIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-02-27 | — | — | WO | disclosed |
| WO-2003004458-A1 | NEW COMPOUNDS | BIOVITRUM AB (SE) | 2003-01-16 | — | — | WO | disclosed |
| EP-1254101-A1 | PROPIONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF DIABETES AND OBESITY | Novo Nordisk A/S (DK) | 2002-11-06 | — | — | EP | disclosed |
| CN-1370176-A | Subsstituted heterocycle fused gamma-carbolines | BRISTOL MYERS SQUIBB CO (US) | 2002-09-18 | — | — | CN | disclosed |
| EP-1192165-A2 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | Bristol-Myers Squibb Pharma Company (US) | 2002-04-03 | — | — | EP | disclosed |
| WO-2001055085-A1 | PROPIONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF DIABETES AND OBESITY | NOVO NORDISK A/S (DK) | 2001-08-02 | — | — | WO | disclosed |
| WO-2000077010-A2 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230026425-A1 | ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | RIPK1, RIPK3, RIPK4 | ENPP2 816/4885TUBB4A 4834/4885TUBB 4764/4885 |
| US-20250206724-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | CDK1, CDK11A, CDK3 | ENPP2 1794/4885TUBB4A 1697/4885TUBB 1261/4885 |
| US-20030073862-A1 | Compounds | PPARG, PPARA, PPARD | ENPP2 914/4885TUBB4A 3528/4885TUBB 3474/4885 |
| US-12435060-B2 | Acylamino bridged heterocyclic compound, and composition and application thereof | RIPK1, RIPK3, RIPK4 | ENPP2 816/4885TUBB4A 4834/4885TUBB 4764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.